The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose

Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients un...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Idan, Campisi-Pfinto, Salvatore, Rozenberg, Orit, Colodner, Raul, Bar-Sela, Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078898/
https://www.ncbi.nlm.nih.gov/pubmed/36856804
http://dx.doi.org/10.1093/oncolo/oyad003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078898/
https://www.ncbi.nlm.nih.gov/pubmed/36856804
http://dx.doi.org/10.1093/oncolo/oyad003

Ejemplares similares